NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
Clinical Trials
47 trialsNCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT03387917 2024-12-02
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
Phase 1 Terminated
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT01279291 2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT04814875 2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Phase 1/2 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT00819221 2022-08-30
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT00785798 2022-04-04
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Yale University
Phase 1/2 Terminated
NCT01485874 2022-02-15
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Hoosier Cancer Research Network
Phase 1 Terminated
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT01170650 2021-09-30
PROCEED
Endocyte
Phase 3 Terminated
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT00744354 2018-01-18
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00426127 2017-12-29
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
University of Iowa
Phase 2 Terminated
NCT00849251 2017-09-08
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
University of Washington
Phase 1/2 Terminated
NCT00837200 2017-07-24
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
Phase 2 Terminated
NCT00604968 2017-06-07
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
Merck Sharp & Dohme LLC
Phase 4 Terminated
NCT01227941 2016-10-19
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Tesaro, Inc.
Phase 1 Terminated
NCT01110603 2016-05-05
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
Tesaro, Inc.
Phase 1 Terminated
NCT02131506 2016-02-02
CAELYX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00779285 2015-07-14
Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 4 Terminated
NCT00176293 2015-04-21
Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer
University of Kentucky
Phase 2 Terminated
NCT00312650 2015-01-12
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT01078441 2015-01-12
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00082095 2014-10-09
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00691912 2014-09-03
MyoPac
University of Magdeburg
Phase 2 Terminated
NCT00183976 2014-05-22
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
University of Southern California
Phase 2 Terminated
NCT01202890 2014-01-08
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00350948 2013-11-27
ASSIST-5
Telik
Phase 3 Terminated
NCT01016054 2013-02-27
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Astellas Pharma Inc
Phase 1 Terminated
NCT00431795 2013-02-13
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00653328 2012-05-23
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00653952 2010-04-27
CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00161239 2009-12-11
LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT00465673 2009-08-06
Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00132756 2006-11-08
Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
Morton Plant Mease Health Care
Phase 1/2 Terminated
NCT00179725 2006-04-12
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene
Phase 1/2 Terminated